(2-Amino-3-methyl-phenyl)-(4-{2-[4-(4-methoxy-benzenesulfonyl)-phenyl]-[1,3]dioxolan-2-yl}-[1,4']bipiperidinyl-1'-yl)-methanone

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-Amino-3-methyl-phenyl)-(4-{2-[4-(4-methoxy-benzenesulfonyl)-phenyl]-[1,3]dioxolan-2-yl}-[1,4']bipiperidinyl-1'-yl)-methanone
• 英文别名: (2-Amino-3-methylphenyl)-[4-[4-[2-[4-(4-methoxyphenyl)sulfonylphenyl]-1,3-dioxolan-2-yl]piperidin-1-yl]piperidin-1-yl]methanone
• 化学式: C₃₄H₄₁N₃O₆S
• 分子量: 619.782
• InChiKey: AEYQIDXHXHKLQR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  44
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• METHODS OF TREATMENT OF FATTY LIVER DISEASE BY PHARMACOLOGICAL ACTIVATION OF CHOLINERGIC PATHWAYS
  申请人：Pavlov Valentin A.

  公开号：US20120322719A1

  公开（公告）日：2012-12-20

  A method of treating a fatty liver disease in a subject. The method comprises administering to the subject an effective amount of a cholinergic pathway stimulating agent, wherein the fatty liver disease is selected from non-alcoholic fatty liver (NAFL), alcoholic fatty liver (AFL), non-alcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), NASH-associated liver fibrosis, ASH-associated liver fibrosis, non-alcoholic cirrhosis, and alcoholic cirrhosis.
• US8865641B2
  申请人：——

  公开号：US8865641B2

  公开（公告）日：2014-10-21